Thus, it may be used as a future therapeutic target in patients with ischemic stroke; (iii) the prognostic value of RBP4 was stronger amongst diabetic patients (OR = 1.12, 95% CI: 1.08–1.6; P<0.001) compared with non-diabetic patients (OR = 1.07, 95% CI: 0.04–1.11; P=0.001); (iv) RBP4 showed a significantly greater discriminatory ability to predict poor functional outcomes as compared with other biomarkers, such as Hs-CRP, FBG, and age. The gene discussed is CRP; the disease is ischemic stroke.